Table 1.
Subject ID | Genotype | Gender | Age | Cohort | Dose alipogene tiparvovec [gc/kg] | Immuno-suppressant regimen |
---|---|---|---|---|---|---|
01 | P207L/P207L | F | 60 | 2 | 3 × 1011 | CsA + MMF |
04 | P207L/P207L | M | 50 | 1 | 3 × 1011 | none |
06 | P207L/P207L | M | 51 | 1 | 3 × 1011 | none |
07 | P207L/P207L | F | 56 | 2 | 3 × 1011 | CsA + MMF |
08 | P207L/P207L | M | 28 | 3 | 1 × 1012 | CsA + MMF |
09 | P207L/G188E | F | 62 | 3 | 1 × 1012 | CsA + MMF |
10 | P207L/D9N | M | 42 | 2 | 3 × 1011 | CsA + MMF |
11 | P207L/P207L | F | 48 | 3 | 1 × 1012 | CsA + MMF |
13 | P207L/G188E | F | 40 | 3 | 1 × 1012 | CsA + MMF |
14 | P207L/P207L | F | 51 | 2 | 3 × 1011 | CsA + MMF |
15 | P207L/P207L | F | 50 | 3 | 1 × 1012 | CsA + MMF |
18 | P207L/P207L | M | 37 | 3 | 1 × 1012 | CsA + MMF |
19 | P207L/P207L | F | 28 | 3 | 1 × 1012 | CsA + MMF |
20 | P207L/P207L | F | 36 | 3 | 1 × 1012 | CsA + MMF |
CsA: cyclosporine A (3mg/kg/day)
MMF: mycophenolate mofetil (2g/day)